Atopic dermatitis

Atopic Dermatitis (AD) usually starts in early childhood - it is estimated that 10-20% of children and 1-3% of adults are affected, making it one of the most common of all skin conditions. AD can have a severe impact on everyday life for both patients and their families. Persistent itching can lead to sleep disturbances, stress, and anxiety, thereby limiting quality of life. AD can also have a psychological depraving effect resulting in social unease and reduced work abilities.

AD is a chronic inflammatory skin disease that manifests as a malfunction of the skin layer, reflecting an underlying dysregulated T cell response to allergens. Studies indicate that it is primarily a genetically determined skin condition that can be triggered or enhanced by a wide range of environmental factors. Common symptoms include rash, skin dryness, cracks, crusting, oozing and intense itching. Breaking of the skin-barrier can introduce various microorganisms causing infections, such as infection with Staphylococcus aureus. Staphylococcus aureus has been linked through several studies to intensifying the inflammatory response, thereby amplifying AD symptoms. A significant unmet medical need in AD still exists today due to the tradeoff between safety, efficacy and convenience of currently available treatments.


UNI50002 cream, a non-steroidal topical PDE4 inhibitor, is being developed by UNION for atopic dermatitis and is currently in Phase 2.


Clinical findings from a mechanistic study conducted by UNION therapeutics have been published in The Journal of Investigative Dermatology.

For full article, please see: ATx201 modulates biomarkers of skin barrier function and cutaneous inflammation in patients with moderate atopic dermatitis.

Back to Pipeline